Thiosemicarbazones reprogram pancreatic cancer bidirectional oncogenic signaling between cancer cells and stellate cells to suppress desmoplasia

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Rahib L, Smith BD, Aizenberg R et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74(11), 2913–2921 (2014).
  Medline CASGoogle Scholar
• 2. Neuzillet C, Tijeras-Raballand A, Bourget P et al. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol. Ther. 155, 80–104 (2015).
  Medline CASGoogle Scholar
• 3. Chand S, O'Hayer K, Blanco FF et al. The landscape of pancreatic cancer therapeutic resistance mechanisms. Int. J. Biol. Sci. 12(3), 273–282 (2016).
  Medline CASGoogle Scholar
• 4. Sagol Ö, Yavuzsen T, Öztop I et al. The effect of apoptotic activity, survivin, Ki-67, and P-glycoprotein expression on prognosis in pancreatic carcinoma. Pancreas. 30(4), 343–348 (2005).
  Medline CASGoogle Scholar
• 5. O'Driscoll L, Walsh N, Larkin A et al. MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma. Anticancer Res. 27(4B), 2115–2120 (2007).
  MedlineGoogle Scholar
• 6. Neesse A, Michl P, Frese KK et al. Stromal biology and therapy in pancreatic cancer. Gut. 60(6), 861–868 (2011).
  MedlineGoogle Scholar
• 7. Vonlaufen A, Joshi S, Qu C et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 68(7), 2085–2093 (2008).
  Medline CASGoogle Scholar
• 8. Dauer P, Nomura A, Saluja A, Banerjee S. Microenvironment in determining chemo-resistance in pancreatic cancer: neighborhood matters. Pancreatology. 17(1), 7–12 (2017).
  Medline CASGoogle Scholar
• 9. Creeden JF, Alganem K, Imami AS et al. Kinome array profiling of patient-derived pancreatic ductal adenocarcinoma identifies differentially active protein tyrosine kinases. Int. J. Mol. Sci. 21(22), 8679 (2020).
  CASGoogle Scholar
• 10. Creeden JF, Alganem K, Imami AS et al. Emerging kinase therapeutic targets in pancreatic ductal adenocarcinoma and pancreatic cancer desmoplasia. Int. J. Mol. Sci. 21(22), 8823 (2020).
  CASGoogle Scholar
• 11. Hassouneh B, Islam M, Nagel T et al. Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol. Cancer Ther. 6(3), 1039–1045 (2007).
  Medline CASGoogle Scholar
• 12. Kalinowski DS, Stefani C, Toyokuni S et al. Redox cycling metals: pedaling their roles in metabolism and their use in the development of novel therapeutics. Biochim. Biophys. Acta, Mol. Cell Res. 1863(4), 727–748 (2016).
  Medline CASGoogle Scholar
• 13. Ishida S, Andreux P, Poitry-Yamate C, Auwerx J, Hanahan D. Bioavailable copper modulates oxidative phosphorylation and growth of tumors. Proc. Natl. Acad. Sci. 110(48), 19507–19512 (2013).
  Medline CASGoogle Scholar
• 14. Lener MR, Scott RJ, Wiechowska-Kozłowska A et al. Serum concentrations of selenium and copper in patients diagnosed with pancreatic cancer. Cancer Res. Treat. Official J. Korean Cancer Association. 48(3), 1056 (2016).
  Medline CASGoogle Scholar
• 15. Kalousová M, Krechler T, Jáchymová M et al. Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study. Tumor Biol. 33(5), 1695–1700 (2012).
  Medline CASGoogle Scholar
• 16. Toshiyama R, Konno M, Eguchi H et al. Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. Oncol. Lett. 15(5), 8125–8133 (2018).
  MedlineGoogle Scholar
• 17. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 57(4), 547–583 (2005).
  Medline CASGoogle Scholar
• 18. Merlot AM, Kalinowski DS, Richardson DR. Novel chelators for cancer treatment: where are we now? Antioxid. Redox Signal. 18(8), 973–1006 (2013).
  Medline CASGoogle Scholar
• 19. Richardson D, Tran E, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood. 86, 4295–4306 (1995).
  Medline CASGoogle Scholar
• 20. Lovejoy DB, Richardson DR. Novel ‘hybrid’ iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood. 100(2), 666–676 (2002).
  Medline CASGoogle Scholar
• 21. Richardson DR, Sharpe PC, Lovejoy DB et al. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J. Med. Chem. 49(22), 6510–6521 (2006).
  Medline CASGoogle Scholar
• 22. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. 103(40), 14901–14906 (2006).
  Medline CASGoogle Scholar
• 23. Yuan J, Lovejoy DB, Richardson DR. Novel di-2-pyridyl–derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood. 104(5), 1450–1458 (2004).
  Medline CASGoogle Scholar
• 24. Kovacevic Z, Chikhani S, Lovejoy DB, Richardson DR. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol. Pharmacol. 80(4), 598–609 (2011).
  Medline CASGoogle Scholar
• 25. Liu W, Xing F, Iiizumi-Gairani M et al. N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol. Med. 4(2), 93–108 (2012).
  MedlineGoogle Scholar
• 26. Yu Y, Rahmanto YS, Richardson D. Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. Br. J. Pharmacol. 165(1), 148–166 (2012).
  Medline CASGoogle Scholar
• 27. Geleta B, Park KC, Jansson PJ et al. Breaking the cycle: Targeting of NDRG1 to inhibit bi-directional oncogenic cross-talk between pancreatic cancer and stroma. FASEB J. 35(2), e21347 (2021). •• This article is of considerable interest as it provides the evidence regarding the inhibition of bidirectional signaling between pancreatic cancer cells and pancreatic stellate cells.
  Medline CASGoogle Scholar
• 28. Kovacevic Z, Menezes SV, Sahni S et al. The metastasis suppressor, N-MYC downstream-regulated gene-1 (NDRG1), down-regulates the ErbB family of receptors to inhibit downstream oncogenic signaling pathways. J. Biol. Chem. 291(3), 1029–1052 (2016).
  Medline CASGoogle Scholar
• 29. Lovejoy DB, Sharp DM, Seebacher N et al. Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. J. Med. Chem. 55(16), 7230–7244 (2012).
  Medline CASGoogle Scholar
• 30. Guo ZL, Richardson DR, Kalinowski DS et al. The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms. J. Hematol. Oncol. 9(1), 1–16 (2016).
  MedlineGoogle Scholar
• 31. Lim SC, Jansson PJ, Assinder SJ et al. Unique targeting of androgen-dependent and-independent AR signaling in prostate cancer to overcome androgen resistance. FASEB J. 34(9), 11511–11528 (2020).
  Medline CASGoogle Scholar
• 32. Sestak V, Stariat J, Cermanova J et al. Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents. Oncotarget. 6(40), 42411 (2015).
  MedlineGoogle Scholar
• 33. Jansson PJ, Kalinowski DS, Lane DJ et al. The renaissance of polypharmacology in the development of anti-cancer therapeutics: inhibition of the ‘triad of death’ in cancer by Di-2-pyridylketone thiosemicarbazones. Pharmacol. Res. 100, 255–260 (2015).
  Medline CASGoogle Scholar
• 34. Lovejoy DB, Jansson PJ, Brunk UT et al. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res. 71(17), 5871–5880 (2011).
  Medline CASGoogle Scholar
• 35. Stacy AE, Palanimuthu D, Bernhardt PV et al. Zinc (II)–thiosemicarbazone complexes are localized to the lysosomal compartment where they transmetallate with copper ions to induce cytotoxicity. J. Med. Chem. 59(10), 4965–4984 (2016).
  Medline CASGoogle Scholar
• 36. Hu M, Carraway KL III. Repurposing cationic amphiphilic drugs and derivatives to engage lysosomal cell death in cancer treatment. Front. Oncol. 2837 (2020).
  Google Scholar
• 37. Stefan SM, Jansson PJ, Kalinowski DS et al. The growing evidence for targeting P-glycoprotein in lysosomes to overcome resistance. Future Med. Chem. 12(6), 473–477 (2020).
  CASGoogle Scholar
• 38. Appelqvist H, Waster P, Kagedal K, Ollinger K. The lysosome: from waste bag to potential therapeutic target. J. Mol. Cell Biol. 5(4), 214–226 (2013).
  Medline CASGoogle Scholar
• 39. Jansson PJ, Yamagishi T, Arvind A et al. Di-2-pyridylketone 4, 4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp). J. Biol. Chem. 290(15), 9588–9603 (2015).
  Medline CASGoogle Scholar
• 40. Seebacher NA, Richardson DR, Jansson PJ. A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC. Cell Death Dis. 7(12), e2510–e2510 (2016).
  Medline CASGoogle Scholar
• 41. Yamagishi T, Sahni S, Sharp DM et al. P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J. Biol. Chem. 288(44), 31761–31771 (2013).
  Medline CASGoogle Scholar
• 42. Stacy AE, Palanimuthu D, Bernhardt PV et al. Structure–activity relationships of di-2-pyridylketone, 2-benzoylpyridine, and 2-acetylpyridine thiosemicarbazones for overcoming Pgp-mediated drug resistance. J. Med. Chem. 59(18), 8601–8620 (2016).
  Medline CASGoogle Scholar
• 43. Seebacher NA, Lane DJ, Jansson PJ, Richardson DR. Glucose modulation induces lysosome formation and increases lysosomotropic drug sequestration via the P-glycoprotein drug transporter. J. Biol. Chem. 291(8), 3796–3820 (2016).
  Medline CASGoogle Scholar
• 44. Le NT, Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood. 104(9), 2967–2975 (2004).
  Medline CASGoogle Scholar
• 45. Hosoi F, Izumi H, Kawahara A et al. N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of κB kinase β expression. Cancer Res. 69(12), 4983–4991 (2009).
  Medline CASGoogle Scholar
• 46. Maruyama Y, Ono M, Kawahara A et al. Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res. 66(12), 6233–6242 (2006).
  Medline CASGoogle Scholar
• 47. Kovacevic Z, Chikhani S, Lui GY et al. The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways. Antioxid. Redox Signal. 18(8), 874–887 (2013).
  Medline CASGoogle Scholar
• 48. Menezes SV, Fouani L, Huang ML et al. The metastasis suppressor, NDRG1, attenuates oncogenic TGF-β and NF-κB signaling to enhance membrane E-cadherin expression in pancreatic cancer cells. Carcinogenesis. 40(6), 805–818 (2019).
  Medline CASGoogle Scholar
• 49. Chen Z, Zhang D, Yue F et al. The iron chelators Dp44mT and DFO inhibit TGF-beta-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J. Biol. Chem. 287(21), 17016–17028 (2012).
  Medline CASGoogle Scholar
• 50. Jin R, Liu W, Menezes S et al. The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of β-catenin through mechanisms involving FRAT1 and PAK4. J. Cell Sci. 127(14), 3116–3130 (2014).
  Medline CASGoogle Scholar
• 51. Liu W, Yue F, Zheng M et al. The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1. Oncotarget. 6(11), 8851 (2015).
  MedlineGoogle Scholar
• 52. Sun J, Zhang D, Zheng Y et al. Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway. Mol. Pharmacol. 83(2), 454–469 (2013).
  Medline CASGoogle Scholar
• 53. Wangpu X, Lu J, Xi R et al. Targeting the metastasis suppressor, N-Myc downstream regulated gene-1, with novel di-2-pyridylketone thiosemicarbazones: Suppression of tumor cell migration and cell-collagen adhesion by inhibiting focal adhesion kinase/paxillin signaling. Mol. Pharmacol. 89(5), 521–540 (2016).
  Medline CASGoogle Scholar
• 54. Park KC, Geleta B, Leck LYW et al. Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding. J. Biol. Chem. 295(2), 481–503 (2020).
  Medline CASGoogle Scholar
• 55. Menezes SV, Kovacevic Z, Richardson DR. The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6. J. Biol. Chem. 294(11), 4045–4064 (2019).
  Medline CASGoogle Scholar
• 56. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat. Rev. Cancer. 7(5), 357–369 (2007).
  Medline CASGoogle Scholar
• 57. Korcsmáros T, Szalay MS, Böde C et al. How to design multi-target drugs: target search options in cellular networks. Expert Opin. Drug Discov. 2(6), 799–808 (2007).
  Medline CASGoogle Scholar
• 58. Campbell PJ, Yachida S, Mudie LJ et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 467(7319), 1109–1113 (2010).
  Medline CASGoogle Scholar
• 59. Pruijn FB, Sturman JR, Liyanage HS et al. Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures. J. Med. Chem. 48(4), 1079–1087 (2005).
  Medline CASGoogle Scholar
• 60. Kleeff J, Korc M, Apte M et al. Pancreatic cancer. Nat. Rev. Dis. Primers. 2(1), 1–22 (2016).
  Google Scholar
• 61. Apte MV, Park S, Phillips PA et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas. 29(3), 179–187 (2004).
  Medline CASGoogle Scholar
• 62. Pothula SP, Xu Z, Goldstein D et al. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. Br. J. Cancer. 114(3), 269–280 (2016).
  Medline CASGoogle Scholar
• 63. Rucki AA, Foley K, Zhang P et al. Heterogeneous stromal signaling within the tumor microenvironment controls the metastasis of pancreatic cancer. Cancer Res. 77(1), 41–52 (2017).
  Medline CASGoogle Scholar
• 64. Tape CJ, Ling S, Dimitriadi M et al. Oncogenic KRAS regulates tumor cell signaling via stromal reciprocation. Cell. 165(4), 910–920 (2016).
  Medline CASGoogle Scholar
• 65. Gu D, Schlotman KE, Xie J. Deciphering the role of hedgehog signaling in pancreatic cancer. J. Biomed. Res. 30(5), 353 (2016).
  MedlineGoogle Scholar
• 66. Kasperczyk H, Baumann B, Debatin KM, FuMa S. Characterization of sonic hedgehog as a novel NF-κB target gene that promotes NF-κB-mediated apoptosis resistance and tumor growth in vivo. FASEB J. 23(1), 21–33 (2009).
  Medline CASGoogle Scholar
• 67. Nakashima H, Nakamura M, Yamaguchi H et al. Nuclear factor-κB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. Cancer Res. 66(14), 7041–7049 (2006).
  Medline CASGoogle Scholar
• 68. Noubissi FK, Goswami S, Sanek NA et al. Wnt signaling stimulates transcriptional outcome of the Hedgehog pathway by stabilizing GLI1 mRNA. Cancer Res. 69(22), 8572–8578 (2009).
  Medline CASGoogle Scholar
• 69. Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int. J. Mol. Sci. 18(7), 1338 (2017).
  Google Scholar
• 70. Liu Q, Liao Q, Zhao Y. Chemotherapy and tumor microenvironment of pancreatic cancer. Cancer Cell Int. 17(1), 1–17 (2017).
  MedlineGoogle Scholar
• 71. Geleta B, Tout FS, Lim SC et al. Targeting Wnt/Tenascin C-mediated cross talk between pancreatic cancer cells and stellate cells via activation of the metastasis suppressor NDRG1. J. Biol. Chem. 101608 (2022). • Provides additional molecular evidence regarding the ability of NDRG1 to inhibit bidirectional crosstalk between pancreatic cancer cells and pancreatic stellate cells.
  MedlineGoogle Scholar
• 72. Pothula SP, Xu Z, Goldstein D et al. Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer. Oncotarget. 8(44), 76722 (2017).
  MedlineGoogle Scholar
• 73. Xu Z, Vonlaufen A, Phillips PA et al. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am. J. Pathol. 177(5), 2585–2596 (2010).
  MedlineGoogle Scholar
• 74. Apte MV, Pirola RC, Wilson JS. Pancreatic stellate cells: a starring role in normal and diseased pancreas. Front. Physiol. 3, 344 (2012).
  MedlineGoogle Scholar
• 75. Fujita H, Ohuchida K, Mizumoto K et al. α-Smooth muscle actin expressing stroma promotes an aggressive tumor biology in pancreatic ductal adenocarcinoma. Pancreas. 39(8), 1254–1262 (2010).
  Medline CASGoogle Scholar